Three Toronto stores raided for selling illegal sex pills

Unauthorized and potentially dangerous health products have been seized from three convenience stores in Toronto.To get more news about vigrx oil, you can visit vigrxplus-original.com official website.

Health Canada is warning the public that 13 unauthorized health products were seized from Danforth Food Market at 2200 Martin Grove Road, All Season Food Market at 1555 Eglinton Avenue W, and Hasty Market at 670 Rexdale Boulevard.
The pills in question — with suggestive names like “All Nite Long,” “ExtenZe” and “Rhino 7 Platinum 5000” — are advertised to improve sexual performance or enhance experience, but do so with substances that are not authorized for sale in Canada or require a prescription.

Danforth Food Market was the worst offender of the three retailers caught selling these products, offering nine different brands of sexual enhancement pills containing unauthorized substances, including yohimbe, mucuna pruriens, and even the prescription-only sildenafil, better known as Viagra.

Health Canada has shared a list of the seized products, the controlled or banned substances they contain, and the retail locations where they were sold.

The government agency warns that consuming these products may pose serious health risks, and encourages members of the public who have purchased these unlicensed medications not to use them.
It is already known from other studies that more than four doses of PrEP a week appear to be fully protective for gay men taking PrEP pills. The figures from HPTN 083 confirmed this, and even strengthened the evidence. Virtually all the infections in gay and bisexual men and transgender women taking oral TDF/FTC in that trial who acquired HIV were taking either no PrEP or less than two doses a week. In fact, while undetectable levels of TDF/FTC in either trial offered zero efficacy, in HPTN 083 even taking some, but less than two, doses a week offered, it was estimated, about 50% efficacy (though statistical uncertainty means the ‘true’ figure could have been anywhere from zero to 70%).

But for anything more than two doses a week, the calculated efficacy was 99%, and even the lower bound of the 95% confidence interval (i.e. the lowest likely ‘true’ doses needed, given statistical uncertainty) was 93% for 2-4 doses a week and 98% or four or more.

The situation for cisgender women taking part in HPTN 084 was very different. If the women managed daily dosing (as measured by DBS) the average likely efficacy was 99%. But if they took 4-6 doses a week it was 88% and 2-4 doses, 80%. But for women who took fewer than two doses, it was statistically equivalent to zero.